SI1858920T1 - Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso - Google Patents

Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso

Info

Publication number
SI1858920T1
SI1858920T1 SI200632047A SI200632047A SI1858920T1 SI 1858920 T1 SI1858920 T1 SI 1858920T1 SI 200632047 A SI200632047 A SI 200632047A SI 200632047 A SI200632047 A SI 200632047A SI 1858920 T1 SI1858920 T1 SI 1858920T1
Authority
SI
Slovenia
Prior art keywords
meningitis
sepsis
proteins
nucleic acids
escherichia coli
Prior art date
Application number
SI200632047A
Other languages
English (en)
Inventor
Mariagrazia Pizza
Laura Serino
Vega Masignani
Herve Tettelin
Scorza Francesco Berlanda
Moriel Danilo Gomes
Nathalie Norais
Maria Rita Fontana
Original Assignee
Glaxosmithkline Biologicals S.A.
J. Craig Venter Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., J. Craig Venter Institute, Inc. filed Critical Glaxosmithkline Biologicals S.A.
Publication of SI1858920T1 publication Critical patent/SI1858920T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200632047A 2005-02-18 2006-02-17 Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso SI1858920T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65463205P 2005-02-18 2005-02-18
US71272005P 2005-08-29 2005-08-29
EP06748228.1A EP1858920B1 (en) 2005-02-18 2006-02-17 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
PCT/US2006/005913 WO2006089264A2 (en) 2005-02-18 2006-02-17 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli

Publications (1)

Publication Number Publication Date
SI1858920T1 true SI1858920T1 (sl) 2016-07-29

Family

ID=36917149

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200632047A SI1858920T1 (sl) 2005-02-18 2006-02-17 Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
SI200632108A SI2351772T1 (sl) 2005-02-18 2006-02-17 Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200632108A SI2351772T1 (sl) 2005-02-18 2006-02-17 Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso

Country Status (18)

Country Link
US (4) US8758764B2 (sl)
EP (2) EP1858920B1 (sl)
JP (2) JP2008529558A (sl)
AU (1) AU2006214064B2 (sl)
CA (1) CA2601924A1 (sl)
CY (2) CY1117732T1 (sl)
DK (2) DK1858920T3 (sl)
ES (2) ES2595363T3 (sl)
HU (2) HUE027400T2 (sl)
IL (2) IL185359A0 (sl)
LT (1) LT2351772T (sl)
MX (1) MX306302B (sl)
NZ (3) NZ561042A (sl)
PL (2) PL2351772T3 (sl)
PT (1) PT2351772T (sl)
SG (1) SG160329A1 (sl)
SI (2) SI1858920T1 (sl)
WO (1) WO2006089264A2 (sl)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
JP4254931B1 (ja) * 2000-10-27 2009-04-15 カイロン ソチエタ ア レスポンサビリタ リミタータ Ａ群連鎖球菌およびｂ群連鎖球菌由来の核酸およびタンパク質
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
EP1896062B1 (en) 2005-06-27 2010-03-31 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
ITMI20081249A1 (it) * 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
JP5332237B2 (ja) * 2008-03-06 2013-11-06 味の素株式会社 Ｌ−システイン生産菌及びｌ−システインの製造法
AU2009294318B2 (en) 2008-09-18 2014-04-24 Novartis Ag Vaccine adjuvant combinations
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010124085A2 (en) * 2009-04-23 2010-10-28 Cornell University Compositions and methods for preventing and treating uterine disease
US9119802B2 (en) * 2009-05-06 2015-09-01 Cornell University E. coli LpfA antigen for prevention and treatment of infectious diseases
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
CN102666571A (zh) 2009-07-07 2012-09-12 诺华有限公司 保守的大肠杆菌免疫原
EP2837386B1 (en) * 2009-07-16 2018-03-07 GlaxoSmithKline Biologicals SA Detoxified Escherichia coli immunogens
EP2277989A1 (en) 2009-07-24 2011-01-26 Technische Universiteit Delft Fermentative glycerol-free ethanol production
EP2470205A1 (en) * 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
ATE557035T1 (de) * 2009-09-10 2012-05-15 Univ Berlin Freie Identifizierung und charakterisierung eines neuartigen aviären pathogenen e. coli (apec) fimbrien-adhäsins
US20120301434A1 (en) * 2009-10-02 2012-11-29 Oslo Universitetssykehus Hf Antibacterial polypeptides and use thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
ES2575215T3 (es) 2009-12-11 2016-06-27 Autifony Therapeutics Limited Derivados de imidazolidindiona
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
CN106421773A (zh) 2010-07-06 2017-02-22 诺华股份有限公司 自我复制rna分子的病毒样递送颗粒
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
EP2590626B1 (en) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes with lipids having an advantageous pka-value for rna delivery
CA3169291A1 (en) 2010-07-06 2012-01-12 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN103384515B (zh) 2010-08-31 2017-02-15 诺华有限公司 适用于脂质体递送编码蛋白质的rna的脂质
HRP20221533T1 (hr) 2010-08-31 2023-02-17 Glaxosmithkline Biologicals Sa Pegilirani liposomi za isporuku rna koja kodira imunogen
EP2719395A1 (en) 2010-09-01 2014-04-16 Novartis AG Adsorption of immunopotentiators to insoluble metal salts
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
MX363307B (es) 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
ES2630029T3 (es) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
JP2014520806A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
AU2012301715B2 (en) 2011-08-31 2017-08-24 Glaxosmithkline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding RNA
WO2013038385A2 (en) 2011-09-14 2013-03-21 Novartis Ag Escherichia coli vaccine combination
KR101359844B1 (ko) * 2012-01-06 2014-02-25 씨제이제일제당 (주) 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법
WO2013108860A1 (ja) * 2012-01-18 2013-07-25 三井化学株式会社 １，５－ペンタメチレンジアミンの製造方法、１，５－ペンタメチレンジイソシアネートの製造方法およびポリイソシアネート組成物の製造方法
LT2822947T (lt) 2012-03-07 2016-10-10 Glaxosmithkline Biologicals Sa Tlr7 agonisto arginino druskos
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
WO2013132041A2 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
CN104812773B (zh) * 2012-07-20 2018-04-06 庆熙大学校产学协力团 表位标记用抗体、杂交瘤细胞株以及其用途
CA2882382A1 (en) 2012-09-18 2014-03-27 Novartis Ag Outer membrane vesicles
MX2015004844A (es) * 2012-10-17 2015-11-16 Enterome Firmas geneticas de trastornos inflamatorios que se relacionan con el higado.
WO2014078270A1 (en) * 2012-11-13 2014-05-22 The General Hospital Corporation In vitro assays for detecting salmonella enterica serotype typhi
WO2014102694A1 (en) 2012-12-24 2014-07-03 Novartis Ag Novel mucinase for use in therapy or prophylaxis
CA2904184C (en) 2013-03-08 2021-09-07 Novartis Ag Lipids and lipid compositions for the delivery of active agents
AU2014227653B2 (en) 2013-03-15 2017-04-20 The General Hospital Corporation Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
KR101525663B1 (ko) * 2013-05-10 2015-06-04 씨제이제일제당 (주) 신규 ｏ-포스포세린 배출 단백질 및 이를 이용한 ｏ-포스포세린의 생산방법
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
KR20150018227A (ko) * 2013-08-09 2015-02-23 삼성전자주식회사 외인성 푸마라아제 유전자를 포함하는 코리네박테리움 및 이를 이용한 c4 디카르복실산의 생산 방법
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US10624934B2 (en) * 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
JP6754694B2 (ja) 2014-03-06 2020-09-16 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル プロバイオティクス製剤および使用のための方法
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
EP4223285A3 (en) 2014-07-16 2023-11-22 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
WO2016037053A1 (en) 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
CN107771214B (zh) * 2015-04-07 2022-01-18 代谢探索者公司 用于具有增加的2,4-二羟基丁酸外排物的优化的2,4-二羟基丁酸产生的修饰的微生物
US20160317615A1 (en) * 2015-05-01 2016-11-03 Jose Javier Lopez GONZALEZ T cell modulator
US11209972B2 (en) 2015-09-02 2021-12-28 D&M Holdings, Inc. Combined tablet screen drag-and-drop interface
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
WO2017086329A1 (ja) * 2015-11-16 2017-05-26 国立大学法人熊本大学 細胞の再プログラミングを誘導する組成物、及び該組成物を用いた多能性細胞の製造方法
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
EP3405479A4 (en) * 2016-01-21 2019-08-21 T2 Biosystems, Inc. NMR METHOD AND SYSTEMS FOR THE FAST DETECTION OF BACTERIA
CN109310730A (zh) 2016-02-17 2019-02-05 佩普蒂康姆有限责任公司 Tlr4活化的肽激动剂和拮抗剂
EP3430168B1 (en) * 2016-03-14 2021-10-20 The Translational Genomics Research Institute Methods and kits to identify klebsiella strains
WO2017158135A1 (en) * 2016-03-16 2017-09-21 Dsm Ip Assets B.V. Microbial production of nicotinic acid riboside
WO2017185249A1 (zh) * 2016-04-27 2017-11-02 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
GB201617548D0 (en) * 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3565589A1 (en) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US11034948B2 (en) 2018-07-09 2021-06-15 Codexis, Inc. Engineered phosphopentomutase variant enzymes
EP3861021A4 (en) * 2018-10-05 2022-06-22 Research Institute at Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR ENZYMATIC DESTRUCTION OF BACTERIAL BIOFILM
KR101991206B1 (ko) * 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101991207B1 (ko) 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101996767B1 (ko) * 2018-11-29 2019-07-04 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
EP3893856A4 (en) * 2018-12-10 2022-10-05 Flagship Pioneering Innovations VI, LLC ACHROMOSOMAL DYNAMIC ACTIVE SYSTEMS
WO2020234498A2 (es) * 2019-05-15 2020-11-26 Universidad De Granada Terapia génica con los genes hokd y ldrb para el tratamiento del cáncer
AU2020297499A1 (en) * 2019-06-21 2022-02-03 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli
CN110441284B (zh) * 2019-07-23 2022-02-15 海南大学 一种可用于痕量检测的表面增强拉曼散射芯片的制备方法及所得产品和应用
US20230041211A1 (en) * 2019-12-20 2023-02-09 Basf Se Decreasing toxicity of terpenes and increasing the production potential in micro-organisms
EP4110283A4 (en) * 2020-02-25 2024-02-28 Synlogic Operating Co Inc RECOMBINANT BACTERIA MANIPULATED FOR THE TREATMENT OF URIC ACID-ASSOCIATED DISEASES AND METHOD OF USE THEREOF
CN111778224B (zh) * 2020-07-20 2021-06-01 成都薇合生物科技有限公司 尿酸酶或其同源酶及其应用
US11767519B2 (en) 2020-08-28 2023-09-26 Codexis, Inc. Engineered amylase variants
CN112391331B (zh) * 2020-11-12 2022-09-27 江南大学 一种过表达GatA基因的重组大肠杆菌及其应用
CN114137209B (zh) * 2021-02-01 2024-03-01 中国水产科学研究院黄海水产研究所 一种快速检测牡蛎疱疹病毒抗原的免疫荧光检测试纸条及应用
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
US20220323576A1 (en) * 2021-04-01 2022-10-13 Janssen Pharmaceuticals, Inc. Production of E. coli O18 Bioconjugates
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023021427A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023022788A1 (en) * 2021-08-18 2023-02-23 The Regents Of The University Of California Methods and compositions for determining risk of autism spectrum disorders
CN113897324B (zh) * 2021-10-13 2023-07-28 云南师范大学 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法
CN114107413B (zh) * 2021-11-03 2023-10-20 江苏香地化学有限公司 一种酶催化胞嘧啶生产胞苷的方法及应用
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023122632A1 (en) * 2021-12-21 2023-06-29 Sri International Dual targeting for cell-specific delivery to the central nervous system
CN114522230A (zh) * 2022-01-11 2022-05-24 上海市伤骨科研究所 一种蓝光和对苯醌联合杀菌方法
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN115286701A (zh) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用
WO2023245129A2 (en) * 2022-06-15 2023-12-21 Quantum-Si Incorporated Directed protein evolution
WO2024083912A1 (en) 2022-10-19 2024-04-25 Glyprovac Aps Glycosylated yghj polypeptides from uropathogenic e. coli
CN118086235A (zh) * 2022-11-28 2024-05-28 宁波酶赛生物工程有限公司 一种合成d-泛解酸的酶催化剂和方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
CA2289219C (en) 1991-03-01 2003-05-20 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1h-imidazo[4,5-c]quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
ES2149276T3 (es) 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1997004110A1 (en) 1995-07-14 1997-02-06 Somatogen, Inc. Methods for increasing protein expression
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO1998022575A2 (en) * 1996-11-22 1998-05-28 Human Genome Sciences, Inc. Nucleotide sequence of escherichia coli pathogenicity islands
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
DE69841807D1 (de) 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
AU759391B2 (en) 1998-02-12 2003-04-10 Wyeth Holdings Corporation Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
EP1093517B1 (en) 1998-05-01 2008-03-05 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000009699A2 (en) 1998-08-14 2000-02-24 Chiron Corporation Method for producing yeast expressed hpv types 6 and 16 capsid proteins
TR200101055T2 (tr) 1998-10-16 2001-09-21 Smithkline Beecham Biologicals S.A. Adjuvan sistemler ve aşılar
EP1133572A4 (en) 1998-11-12 2005-06-15 Univ California GENOME SEQUENCE OF CHLAMYDIA PNEUMONIAE
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
EP1955709B1 (en) 1999-03-26 2012-03-14 Vical Incorporated Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CA2371032A1 (en) 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
AU5561599A (en) 1999-05-05 2000-11-21 Sterrenbeld Biotechnologie North America, Inc. Dna promoter sequence for gene expression
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CN1391483A (zh) 1999-09-24 2003-01-15 史密丝克莱恩比彻姆生物有限公司 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
WO2001064922A2 (en) 2000-02-28 2001-09-07 Chiron Spa Heterologous expression of neisserial proteins
AU2001277840A1 (en) 2000-03-07 2002-03-04 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2004512817A (ja) * 2000-03-10 2004-04-30 アンスティテュ　ナショナル　ド　ラ　サンテ　エ　ド　ラ　ルシェルシュ　メディカル　（イ．エヌ．エス．エ．エール．エム．） 大腸菌から単離される、ｂ２／ｄ＋ａ−型のポリヌクレオチド、ならびにこれらのポリヌクレオチドとそのポリペプチドの生物学的使用
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
AU2002246592A1 (en) * 2000-10-19 2002-08-06 Wisconsin Alumni Research Foundation Dna sequences of escherichia coli cft073
JP4254931B1 (ja) 2000-10-27 2009-04-15 カイロン ソチエタ ア レスポンサビリタ リミタータ Ａ群連鎖球菌およびｂ群連鎖球菌由来の核酸およびタンパク質
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
AU2002245636B2 (en) 2001-03-09 2004-10-14 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
IL162137A0 (en) 2001-11-27 2005-11-20 Anadys Pharmaceuticals Inc D-ribofuranosylthiazolo -3-Ä4,5-dÜpyridimine nucl eosides and uses thereof
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20030165870A1 (en) * 2002-03-01 2003-09-04 Blattner Frederick R. Novel sequences of E. coli CFT073
EP1342784A1 (en) * 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
FR2842210B1 (fr) 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
CN1688573A (zh) 2002-08-23 2005-10-26 希龙公司 糖原合成酶激酶3的吡咯基抑制剂
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20040209370A1 (en) 2002-12-19 2004-10-21 Wonchul Suh Method for chromosomal engineering
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
CA2513655C (en) 2003-01-21 2011-11-22 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP1441036A1 (en) 2003-01-27 2004-07-28 Université de Nantes Method for the identification and isolation of strong bacterial promoters
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
BRPI0411857A (pt) 2003-06-26 2006-05-23 Chiron Corp composições imunogênicas para chlamydia trachomatis
JP4049045B2 (ja) 2003-07-28 2008-02-20 トヨタ自動車株式会社 蓄熱装置付きエンジンシステム
EP1721283B1 (en) * 2004-02-06 2022-11-30 Council of Scientific and Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso

Also Published As

Publication number Publication date
EP1858920B1 (en) 2016-02-03
IL185359A0 (en) 2008-02-09
MX306302B (en) 2012-12-19
AU2006214064B2 (en) 2012-04-26
HUE027400T2 (en) 2016-10-28
DK1858920T3 (en) 2016-02-29
SG160329A1 (en) 2010-04-29
EP2351772A1 (en) 2011-08-03
US20080193470A1 (en) 2008-08-14
US9334313B2 (en) 2016-05-10
EP1858920A2 (en) 2007-11-28
IL206012A0 (en) 2010-11-30
AU2006214064A1 (en) 2006-08-24
US8758764B2 (en) 2014-06-24
PT2351772T (pt) 2016-09-22
SI2351772T1 (sl) 2016-11-30
LT2351772T (lt) 2016-10-10
WO2006089264A3 (en) 2007-04-05
US20140356389A1 (en) 2014-12-04
US20160244489A1 (en) 2016-08-25
CY1117732T1 (el) 2017-05-17
WO2006089264A8 (en) 2008-03-06
DK2351772T3 (en) 2016-09-05
EP2351772B1 (en) 2016-07-13
JP2008529558A (ja) 2008-08-07
NZ597769A (en) 2013-09-27
NZ561042A (en) 2011-03-31
CY1118149T1 (el) 2017-06-28
NZ597685A (en) 2013-12-20
PL2351772T3 (pl) 2017-01-31
MX2007010043A (en) 2008-08-29
US10035826B2 (en) 2018-07-31
ES2569654T3 (es) 2016-05-12
CA2601924A1 (en) 2006-08-24
WO2006089264A2 (en) 2006-08-24
HUE030881T2 (en) 2017-06-28
US20180298064A1 (en) 2018-10-18
ES2595363T3 (es) 2016-12-29
PL1858920T3 (pl) 2016-12-30
JP2012152228A (ja) 2012-08-16

Similar Documents

Publication Publication Date Title
IL206012A0 (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP2037737A4 (en) PROTEINS, NUCLEIC ACIDS FOR THEIR CODING AND CORRESPONDING USES.
IL185547A0 (en) Lipocalin protein
EP1856291A4 (en) NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
GB0507537D0 (en) Protein resistant surfaces
IL188611A (en) Type 1sp polypeptides are altered at the n-terminal end and used
IL173764A0 (en) Amino acids with affinity for the alpha2delta-protein
EP1725661A4 (en) POLYNUCLEOTIDE FOR THE DETECTION OF SCHERICHIA COLI O157
EP1883291A4 (en) GEN FOR HIGH CORN PROPERTIES
EP2046816A4 (en) STREPTOCOCCUS G PROTEIN VARIANT MARKED BY CYSTEINE
IL193699A0 (en) Proteins, nucleic acids and medicaments
EP2099467A4 (en) ATAP PEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND METHODS OF USING SAME
EP1870463A4 (en) HIGH AFFINES RNA APTAMERMOLEKÜL FOR GLUTATHIONE S-TRANSFERASE PROTEIN
EP1925670A4 (en) HIGH EXPRESSION ESCHERICHIA COLI VECTOR AND USES THEREOF
EP1759000A4 (en) POLYNUCLEOTIDES FOR DETECTION OF ESCHERICHIA COLI
GB0724832D0 (en) Proteins and nucleic acids
GB0511861D0 (en) Proteins
GB0522113D0 (en) vWFA-domain containing proteins
EP1956090A4 (en) NOVEL PROTEIN AND DNA ENCODING THE PROTEIN
GB0513505D0 (en) Proteins
GB0514481D0 (en) Proteins
GB0514788D0 (en) Proteins
GB0518460D0 (en) Protein assay
GB0515438D0 (en) Protein
GB0515180D0 (en) Protein